Older adults with subthreshold depression Mental and Behavioural Disorders
Conditions
Interventions
This cluster-randomized controlled trial will enroll a total of 92 older adults with subthreshold depression from six communities, who will be randomly assigned to (1:1 ratio) either a Baduanjin inter
Sponsors
Shandong University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age >=60 years 2. Clinically relevant depressive symptoms (Geriatric Depression Scale-15 [GDS-15] score >=5) 3. No regular physical exercise within the past year (regular exercise defined as 3–4 sessions/week, 30 minutes/session, sustained for >=3 months) 4. Provided informed consent
Exclusion criteria
Exclusion criteria: 1. History of depression, bipolar disorder or other psychiatric disorders 2. Contraindications to exercise (e.g., cardiovascular or cerebrovascular diseases, musculoskeletal disorders, neurological disorders) 3. Severe cognitive impairment, MMSE score <=24 4. Current receiving structured psychotherapeutic interventions 5. Contraindications to MRI (e.g., claustrophobia, implanted metal devices such as cardiac pacemakers, cochlear implants, artificial heart valves; if MRI was used)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depressive symptoms measured using the 10-item Center for Epidemiologic Studies Depression Scale at baseline, post-intervention and one-month follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| The following secondary outcome measures will be assessed at baseline, post-intervention and one-month follow-up: 1. Cognitive performance will be measured using the Stroop test 2. Anxiety symptoms will be measured using the 7-item Generalized Anxiety Disorder scale 3. Physical frailty will be measured using the Fried frailty phenotype 4. Sleep quality will be measured using the Pittsburgh Sleep Quality Index 5. Heart rate variability will be measured using a physiological monitoring system (DHD-6000, DonghuaYuan Medical Co., Ltd., China) 6. Biochemical parameters will be measured using commercial ELISA kits 7. Gut microbiome will be measured using 16S rRNA gene amplification 8. Magnetic resonance imaging will be collected using a 3.0-T GE MR750 scanner | — |
Countries
China
Contacts
Public ContactBenke Xu
Outcome results
None listed